Back to Search
Start Over
Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.
- Source :
-
Journal of dermatological case reports [J Dermatol Case Rep] 2015 Sep 30; Vol. 9 (3), pp. 62-6. Date of Electronic Publication: 2015 Sep 30 (Print Publication: 2015). - Publication Year :
- 2015
-
Abstract
- Background: Pyoderma gangraenosum is an immune-mediated, inflammatory, neutrophilic dermatosis of unknown etiology, which represents one of the extraintestinal manifestations of inflammatory bowel disease. It is a rare disease that occurs in less than 1% of patients with inflammatory bowel disease and with the same ratio in patients with Crohn's disease and ulcerative colitis.<br />Main Observations: A 36-year-old woman was diagnosed with ulcerative colitis 6 years before admission to our dermatology department with an acute disseminated pyoderma gangraenosum with mucosal involvement, during a flare of ulcerative colitis. Disease progression was interrupted by intravenous administration of the tumor necrosis factor-α inhibitor infliximab at 5 mg/kg at weeks 0, 2, and 6 (1st cycle) and every 8 weeks thereafter. Improvement of intestinal, skin and oral manifestations was evident already after the 1st cycle of treatment and has been maintained since (at least 16 months).<br />Conclusions: This case report is one of very few on disseminated pyoderma gangraenosum with oral involvement complicating ulcerative colitis, where infliximab was shown to have a rapid efficacy on skin, mucosal and bowel symptoms.
Details
- Language :
- English
- ISSN :
- 1898-7249
- Volume :
- 9
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of dermatological case reports
- Publication Type :
- Report
- Accession number :
- 26512301
- Full Text :
- https://doi.org/10.3315/jdcr.2015.1206